Display options
Cite
Donofrio G, Tebaldi G, Lanzardo S, et al. Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells. Oncoimmunology. 2018;7(12):e1494108doi: 10.1080/2162402X.2018.1494108.
Donofrio, G., Tebaldi, G., Lanzardo, S., Ruiu, R., Bolli, E., Ballatore, A., Rolih, V., Macchi, F., Conti, L., & Cavallo, F. (2018). Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells. Oncoimmunology, 7(12), e1494108. https://doi.org/10.1080/2162402X.2018.1494108
Donofrio, Gaetano, et al. "Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells." Oncoimmunology vol. 7,12 (2018): e1494108. doi: https://doi.org/10.1080/2162402X.2018.1494108
Donofrio G, Tebaldi G, Lanzardo S, Ruiu R, Bolli E, Ballatore A, Rolih V, Macchi F, Conti L, Cavallo F. Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells. Oncoimmunology. 2018 Sep 06;7(12):e1494108. doi: 10.1080/2162402X.2018.1494108. eCollection 2018. PMID: 30524888; PMCID: PMC6279326.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2018 Sep 06;7(12):e1494108. doi: 10.1080/2162402X.2018.1494108. eCollection 2018.

Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells.

Oncoimmunology

Gaetano Donofrio, Giulia Tebaldi, Stefania Lanzardo, Roberto Ruiu, Elisabetta Bolli, Andrea Ballatore, Valeria Rolih, Francesca Macchi, Laura Conti, Federica Cavallo

Affiliations

  1. Department of Medical Veterinary Science, Università degli Studi di Parma, Parma, Italy.
  2. Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, Università degli Studi di Torino, Torino, Italy.

PMID: 30524888 PMCID: PMC6279326 DOI: 10.1080/2162402X.2018.1494108

Abstract

Despite marked advancements in its treatment, breast cancer is still the second leading cause of cancer death in women, due to relapses and distal metastases. Breast cancer stem cells (CSCs), are a cellular reservoir for recurrence, metastatic evolution and disease progression, making the development of novel therapeutics that target CSCs, and thereby inhibit metastases, an urgent need. We have previously demonstrated that the cystine-glutamate antiporter xCT (SLC7A11), a protein that was shown to be overexpressed in mammary CSCs and that plays a key role in the maintenance of their redox balance, self-renewal and resistance to chemotherapy, is a potential target for mammary cancer immunotherapy. This paper reports on the development of an anti-xCT viral vaccine that is based on the bovine herpesvirus 4 (BoHV-4) vector, which we have previously showed to be a safe vaccine that can transduce cells

Keywords: Mammary cancer; bovine herpesvirus 4-based vector; cancer stem cell; immunotherapy; xCT

References

  1. Vaccine. 2013 Aug 20;31(37):3906-14 - PubMed
  2. Nat Commun. 2017 Apr 21;8:15074 - PubMed
  3. Oncotarget. 2017 Dec 7;8(69):113373-113402 - PubMed
  4. Oncoimmunology. 2016 Nov 8;5(12):e1253653 - PubMed
  5. Future Oncol. 2018 Apr;14(10):927-936 - PubMed
  6. PLoS One. 2017 Aug 17;12(8):e0182786 - PubMed
  7. Microbes Infect. 2006 Mar;8(3):898-904 - PubMed
  8. FASEB J. 2013 Dec;27(12):4731-44 - PubMed
  9. Front Immunol. 2017 Feb 23;8:194 - PubMed
  10. Oncoimmunology. 2017 Dec 6;7(3):e1408746 - PubMed
  11. Gastroenterology. 2000 Nov;119(5):1209-18 - PubMed
  12. Ann Neurol. 2009 May;65(5):499-509 - PubMed
  13. BMC Vet Res. 2013 Jan 09;9:6 - PubMed
  14. Cancer Lett. 2015 Nov 1;368(1):88-96 - PubMed
  15. J Immunol. 2014 Jun 1;192(11):5434-41 - PubMed
  16. J Cell Biol. 2012 Aug 6;198(3):281-93 - PubMed
  17. Oncoimmunology. 2015 Aug 31;5(3):e1082705 - PubMed
  18. CA Cancer J Clin. 2017 Jan;67(1):7-30 - PubMed
  19. J Mol Biol. 1998 Aug 7;281(1):183-201 - PubMed
  20. Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):E4600-9 - PubMed
  21. Amino Acids. 2012 Jan;42(1):231-46 - PubMed
  22. Nucleic Acids Res. 2005 Feb 24;33(4):e36 - PubMed
  23. Clin Cancer Res. 2010 Jan 1;16(1):45-55 - PubMed
  24. Neuro Oncol. 2012 Mar;14(3):288-301 - PubMed
  25. Semin Cancer Biol. 2017 Jun;44:10-24 - PubMed
  26. Front Immunol. 2017 Oct 25;8:1402 - PubMed
  27. J Biol Chem. 2005 Nov 11;280(45):37423-9 - PubMed
  28. Nat Commun. 2017 Nov 21;8(1):1636 - PubMed
  29. Hum Vaccin Immunother. 2017 Mar 4;13(3):528-532 - PubMed
  30. Vaccine. 2008 Nov 11;26(48):6031-42 - PubMed
  31. BMC Biotechnol. 2007 Oct 18;7:68 - PubMed
  32. PLoS Negl Trop Dis. 2015 Jun 18;9(6):e0003850 - PubMed
  33. Vaccine. 2011 Apr 5;29(16):3074-82 - PubMed
  34. J Virol Methods. 2010 Nov;169(2):420-4 - PubMed
  35. Oncogene. 2013 Oct 31;32(44):5191-8 - PubMed
  36. Oncotarget. 2016 Mar 15;7(11):11756-69 - PubMed
  37. Sci Rep. 2015 Feb 11;5:8380 - PubMed
  38. Oncol Rep. 2015 Mar;33(3):1465-74 - PubMed
  39. Cancer Res. 2009 Oct 1;69(19):7507-11 - PubMed
  40. Nat Commun. 2017 Dec 21;8(1):2255 - PubMed
  41. J Immunol. 2012 Feb 1;188(3):1011-8 - PubMed
  42. J Biol Chem. 1999 Apr 23;274(17):11455-8 - PubMed
  43. Oxid Med Cell Longev. 2016;2016:2428153 - PubMed
  44. J Biol Chem. 2016 Apr 29;291(18):9700-11 - PubMed
  45. Nanoscale. 2015 Apr 21;7(15):6527-33 - PubMed
  46. Future Oncol. 2005 Feb;1(1):57-66 - PubMed
  47. J Virol Methods. 2002 Mar;101(1-2):49-61 - PubMed
  48. Anticancer Res. 2015 Feb;35(2):677-82 - PubMed
  49. PLoS One. 2013;8(1):e52758 - PubMed
  50. Cancer Cell. 2013 Oct 14;24(4):450-65 - PubMed
  51. Cancer Res. 2010 Jan 1;70(1):68-77 - PubMed
  52. Cancer Immunol Immunother. 2018 Jun 15;:null - PubMed
  53. J Immunol. 2006 Dec 1;177(11):7626-33 - PubMed
  54. Oncotarget. 2016 Oct 11;7(41):66713-66727 - PubMed
  55. Adv Immunol. 2016;130:191-249 - PubMed
  56. Clin Vaccine Immunol. 2009 Nov;16(11):1675-86 - PubMed
  57. Biomed Res Int. 2014;2014:534969 - PubMed
  58. J Clin Oncol. 2016 Mar 20;34(9):927-35 - PubMed
  59. Oncogene. 2009 Jan 29;28(4):599-609 - PubMed
  60. Cancer Res. 2016 Jan 1;76(1):62-72 - PubMed
  61. Expert Rev Vaccines. 2013 Dec;12(12):1449-63 - PubMed
  62. Oncoimmunology. 2017 Feb 23;6(3):e1284718 - PubMed
  63. J Cell Physiol. 2008 Jun;215(3):593-602 - PubMed

Publication Types